The establishment of the functional hemogenic endothelium, which can simultaneously
generate endothelial cells and hematopoietic cells, is an indispensable process to differentiate
pluripotent stem cells (PSCs) into myeloid and lymphoid lineage cells.

The long-term goal of my team is to develop a stable protocol for creating functional
natural killer (NK) cells using functional hemogenic endothelium (HE). Currently,
we are integrating single cell RNA sequencing methods into the study of
HE generation and differentiation.

2. We also have expertise in humanized mouse (hu-mouse) model as a solid in vivo platform to
screen potential therapeutic cells differentiated from pluripotent stem cells.
Our contributions to this area have been delineating the anti-tumor effects of NK cells in vivo and
vitro system. By utilizing hu-mouse tumor model, we are investigating the anti-tumor effects of
therapeutic cells to inhibit the tumor progression by exploiting NK cells.

In CARI, our lab is working on development of the functional NK cells from PSCs to suppress the
tumors such as solid tumors as well as hematologic malignancy.